key: cord-0705639-y4z6bbr2
authors: Thomson, George
title: COVID‐19: Social distancing, ACE 2 receptors, protease inhibitors and beyond?
date: 2020-04-06
journal: Int J Clin Pract
DOI: 10.1111/ijcp.13503
sha: 979f39e032af15230e585e4a3d59b7dd668f35fd
doc_id: 705639
cord_uid: y4z6bbr2

I am most grateful to Dr Stein for his thoughtful and considered response to my recent letter(1) . However, completely as he predicted, his answers only raised more questions. I was struck by the analysis of the known mortality data from COVID-19. It is interesting that for a respiratory pathogen, risk of mortality seems to be lower for those with underlying respiratory disease than with pre-existing cardiac pathology.

Sir I am most grateful to Dr Stein for his thoughtful and considered response to my recent letter. 1 However, completely as he predicted, his answers only raised more questions.

I was struck by the analysis of the known mortality data from COVID-19. It is interesting that for a respiratory pathogen, risk of mortality seems to be lower for those with underlying respiratory disease than with pre-existing cardiac pathology. Moreover, the data cited by Dr Stein suggest that pre-existing diabetes is a higher risk for mortality than lung disease, and that pre-existing hypertension confers almost the same risk of death from COVID-19 as underlying lung disease. These findings are unexpected, and surely worthy of further exploration.

In his original editorial, 2 Dr Stein pointed to the fact that modern science has the ability to evaluate new pathogens more rapidly than was ever the case previously. Consequently, much is now already established about the molecular biology surrounding SARS-Cov-2, the viral pathogen associated with COVID-19.

SARS-Cov-2 appears to need to bind to the ACE 2 receptor to enable it to infect host cells, coupled with a reliance on the cellular serine protease TMPRSS2 which also seems to be a determinant of the viruses ability to infect cells. 3 These authors seem to point to the possibility that the clinically proven serine protease inhibitor camostat mesylate, which is active against TMPRSS2 partially blocked SARS-Cov-2 entry into cells and is thus a potential target as an agent to mitigate the impact of SARS-Cov-2 in individuals affected by COVID-19. They note that at present this agent is licenced for human use in Japan to treat an unrelated condition. Equally, it is possible that intervening with an agent which inhibits the ACE receptors may confer therapeutic benefit in those suffering from COVID-19. 5 However, one cannot help but speculate that the increased and somewhat unexpected mortality risk from COVID-19

in those groups where a high prevalence of ACEI and ARB treatment might be expected is somewhat troubling.

In this context, current data appear to conflict. There is some small-scale evidence that prior use of ACEI/ARB drugs in those with cardiovascular disease did not affect outcomes. 6 However, this was a very small study and it would be helpful if the data in respect of any risk imposed by pre-existing ACEI/ARB therapy could now be verified given the much larger databases that must now be available to the global scientific community since this publication early in the evolution of the COVID-19 pandemic. Other authors have speculated that use of ACEI/ARB might actually be a potentially beneficial intervention in those, presumably ACEI/ARB-naïve patients, who develop

COVID-19 and rationally layered social distancing

coronavirus: Learning curves, lessons, and the weakest link

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; Epub ahead of print

Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors

Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics

Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia. Zhi Zhonghua Jie He He Hu Xi Za

Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model